Rede D'Or São Luiz (RDOR3) investor relations material

Executive summary

• Achieved record gross revenue of R$9.9 billion in Q2 2026, up 9.9% year-over-year, with strong growth in surgeries and oncology services, and net income rising 9.7% to R$1.2 billion.

• EBITDA reached R$2.9 billion, up 18.2% year-over-year, with margin improvement and a 92.2% EBITDA conversion rate.

• SulAmérica portfolio saw net revenue grow 6.9% year-over-year to R$8.7 billion, with a 53.4% increase in EBITDA and record growth in dental and healthcare beneficiaries.

• Operations span hospital services, insurance, private pension, and asset management, with 76 hospitals and over 10,000 beds.

• Sustained focus on procurement, technology, operational excellence, and sustainability, with recognition for hospital quality.

Financial highlights

• Consolidated gross revenue for Q2 2026 was R$16.0 billion, up 5.9% year-over-year; H1 2026 consolidated net revenue reached R$29.0 billion, up from R$26.9 billion.

• Oncology gross revenue in Q2 2026 was R$1.149 billion, up 22.3% year-over-year, with a 15.2% rise in infusion volume and a 6.1% higher average ticket.

• Surgery volume reached 151,000 in Q2 2026, up 10.6% year-over-year; elective surgeries grew 11.5% and made up 72.8% of total.

• Gross profit rose 20.1% year-over-year to R$2.3 billion, with gross margin expanding by 2.3 percentage points.

• Cash flow for the semester was R$5.4 billion, representing a 92.2% EBITDA conversion rate.

Outlook and guidance

• Continued focus on operational efficiency, margin improvement, and sustainable growth across all segments, with over 20 expansion projects expected to deliver 2,690 new beds by 2028.

• Ongoing investments in hospital infrastructure, greenfield and brownfield projects, and expansion in oncology and high-occupancy hospitals.

• No explicit forward-looking financial guidance provided, but management remains optimistic about future growth and sector sustainability.